Healthcare
34/100
34/100Is HIMS-Hims & Hers Health, a buy?
Wednesday 24 June 2026
Why now: This is not a good time to buy based on the provided live universe technicals, which show no pre-breakout or confirmed-breakout condition. The only defensible “why now” is to monitor for stabilization after the recent profitability shock and for a real trend reset that shows up in the tape.
Upside: If the company delivers on its 2026 outlook and returns to steadier margin performance, a re-rating back toward prior sentiment could produce material upside from here. That upside is not dependable enough today to justify a long-term buy without clearer proof in results and price trend.
Risks: The biggest risk is that the pivot in weight-loss offerings leads to structurally lower margins and weaker marketing efficiency than investors expect. A second risk is that ongoing dilution and acquisition integration distract from fixing core profitability.
Scorecard
Read:Strong metricsSolid metricsSelectiveCautionUnfavourableN/A
| Scorecard | 34/100 | |
|---|---|---|
| Company Detail | HIMS - Hims & Hers Health, Inc. | |
| Price as at 23 June 2026 | $32.96 | |
| Market cap | $7.6B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 0/20 | |
| Rev/EPS Momentum /20 | 4/20 | |
| Business Quality /15 | 7/15 | |
| Balance Sheet /15 | 10/15 | |
| Valuation /10 | 4/10 | |
| Industry Relative Strength /10 | 0/10 | |
| Macro / Sector Tailwind /10 | 9/10 | |
| Growth (mechanical) | ||
| Cash runway | Cash generative | |
| Revenue YoY | +59.0% | |
| EPS YoY | -3.8% | |
| FCF YoY | -71.1% | |
| Gross margin | 73.8% | |
| Valuation & Trend | ||
| Trailing P/E | — | |
| Forward P/E | 37.0x | |
| RSI (14d) | 62 | |
| vs 50d SMA | +21.2% | |
| Support cushion | −9.2% | |
| Sentiment | ||
| Wall Street verdict | Disagrees | |
| News tone | Quiet | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Wednesday 24 June 2026
What they do
Hims & Hers Health sells subscription-based telehealth and pharmacy products through its digital platform, including treatments for sexual health, hair loss, dermatology, mental health, and weight management. It makes money from online visits, prescriptions, and recurring product subscriptions fulfilled through partner and owned pharmacy operations.
Leadership
Andrew DudumCEO
Andrew Dudum has served as Chief Executive Officer since January 2021.
Yemi OkupeCFO
Yemi Okupe has served as Chief Financial Officer since January 2022.
Summary thesis
- Hims & Hers sits in a real long-term demand area: convenient access to ongoing care for chronic and lifestyle-related conditions.
- The platform model and subscription approach can work over time, but the current investment question is execution and profit durability, not addressable market size.
- Right now, the company is showing that growth can slow quickly and margins can compress when product mix changes.
- Until profitability stabilizes and the stock’s trend improves, this is more of a watchlist name than a long-term core holding.
Wall Street alignment
Wall Street: Wall Street disagrees (2/4 negative)
Analyst consensus
Hold (2.75, 14 analysts) · -17% upside
Institutional ownership
70% institutions, insiders 5.5%
Short interest
32.6% of float short · 2.8 d-to-cover
Smart money tape
+1 net (acc 1 / dist 0, last 26d)
Recent news
News Quiet · last 7d
Show 1 headline from the last 7d
2026-06-18Analyst+supportive
Barclays raises Hims and Hers Health price target to 39 dollars and keeps overweight rating ↗ · Reuters
Barclays increased its price target to 39 dollars from 29 dollars and maintained an overweight rating, citing accelerating demand indicators tied to the company’s branded weight loss drug offering. A supportive rating change can strengthen the near-term momentum narrative and investor confidence in growth through weight loss products.
Dividends
Pays no regular dividend.
Technicals
Price
$32.96
RSI (14d)
62.2
50d SMA
$27.19
200d SMA
$33.23
vs 50d SMA
+21.2%
vs 200d SMA
-0.8%
Support (swing low)
$29.92 −9.2%
Next swing high (swing high)
$36.45 +10.6%
Close as of 2026-06-23.
Score breakdown
Scores 34 out of 100 — a mixed overall grade. Sector fit scored highest. Balance sheet was fair but not a standout driver. Business quality and valuation weighed on the total. The setup fails the published technical gate in the provided live universe (no confirmed breakout, no 200-day uptrend flag, and no verified reclaim). Fundamentals also weakened sharply in the most recent quarter, so this cannot be treated as a high-conviction long-term candidate at this moment.
Component scores are on the scorecard above.
Momentum evidence
- The live universe technical snapshot provided is effectively a fail across the board: no price data, no breakout state, no rising 200-day confirmation, and no reclaim signal.
- Because of that, there is no credible momentum-based “why now” to support an investment entry today, even if the longer-term story is attractive.
Fundamental evidence
- In the first quarter of 2026, revenue was $608.1 million, up 4% year over year, which is modest growth for a business that investors often price as a high-growth platform.
- The company swung to a GAAP net loss of $92.1 million versus GAAP net income of $49.5 million in the year-ago quarter, alongside a meaningful step-down in adjusted profitability.
- Gross margin fell to about 65% from about 73% a year earlier, tied to the business shift in weight-loss offerings and related charges.
- On cash generation, the company reported negative free cash flow in the quarter, and profitability was also pressured by restructuring and other one-time items.
- Balance sheet liquidity appears adequate, with sizable cash and investment balances reported on the most recent quarterly filing, but it also carries meaningful long-term debt and has continued share count growth over time.
Cash runway: Cash generative (latest annual free cash flow is positive).
Valuation view
At today’s market value, the stock still prices in a strong long-term growth path and a return to healthier margins. That is a tough fit right after a quarter that showed slower growth, a sharp margin drop, and negative free cash flow, especially when many healthcare peers with steadier profitability can be owned at more forgiving risk profiles.
Macro tailwind
Consumer healthcare is still shifting toward digital access and at-home delivery, which supports demand for convenient, recurring care models. The tailwind is real, but the market is currently demanding proof of profitable growth, not just category expansion.
What to watch
Upcoming (1–6 months)
- The next quarterly earnings report and guidance update, with a focus on whether gross margin and adjusted profitability rebound after the weight-loss product mix changes.
Ongoing
- Gross margin, marketing efficiency, and free cash flow trend; these must stabilize to support a long-term holding case.
Long-term case
Over multiple years, the best-case outcome is a scaled subscription healthcare brand that expands into additional conditions and geographies while lowering fulfillment and service costs per customer. The long-term case depends on durable customer retention, improving unit economics as the platform grows, and avoiding regulatory or partner shocks in sensitive categories like weight management.
Risks & invalidation
Risks
- Margins and customer acquisition costs may remain structurally worse after the weight-loss shift, limiting profitability even if revenue grows.
- Regulatory, pharmacy, and partner risks in telehealth and weight management could disrupt offerings, pricing, or supply.
- Share dilution and acquisition integration could reduce per-share value if the business does not compound profits.
Breaks the thesis
- If the stock fails to reclaim and hold key longer-term trend levels (especially a sustained move back above the 200-day moving average) and fundamentals do not show improving margins within the next one to two quarters, the long-term investment thesis should be treated as broken.
Bottom line
Do not buy this stock for a long-term holding right now. The recent quarter showed a sharp deterioration in profitability and cash generation, and the provided live technical snapshot does not support a healthy uptrend. Keep it on a watchlist, but wait for clear evidence that margins and cash flow are stabilizing before considering ownership.